AnaptysBio Inc (ANAB.OQ)
ANAB.OQ on NASDAQ Stock Exchange Global Select Market
91.67USD
20 Apr 2018
91.67USD
20 Apr 2018
Change (% chg)
$0.80 (+0.88%)
$0.80 (+0.88%)
Prev Close
$90.87
$90.87
Open
$90.39
$90.39
Day's High
$92.55
$92.55
Day's Low
$90.00
$90.00
Volume
91,314
91,314
Avg. Vol
143,960
143,960
52-wk High
$134.00
$134.00
52-wk Low
$18.18
$18.18
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.49 | December | 21 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 3 | 4 | 4 | 4 |
| (2) OUTPERFORM | 3 | 4 | 4 | 4 |
| (3) HOLD | 1 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.71 | 1.50 | 1.50 | 1.50 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 5 | 1.65 | 5.00 | 0.00 | 1.50 |
| Quarter Ending Sep-18 | 6 | 2.04 | 5.00 | 0.00 | 1.50 |
| Year Ending Dec-18 | 7 | 6.86 | 16.00 | 0.00 | 11.40 |
| Year Ending Dec-19 | 7 | 14.86 | 56.10 | 0.00 | 26.90 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 5 | -0.49 | -0.37 | -0.54 | -0.72 |
| Quarter Ending Sep-18 | 5 | -0.58 | -0.45 | -0.68 | -0.83 |
| Year Ending Dec-18 | 7 | -2.28 | -1.62 | -2.90 | -3.67 |
| Year Ending Dec-19 | 7 | -3.29 | -2.80 | -4.05 | -2.97 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 0.87 | 3.00 | 2.13 | 244.91 |
| Quarter Ending Sep-17 | 2.32 | 0.00 | 2.32 | 100.00 |
| Quarter Ending Jun-17 | 3.34 | 7.00 | 3.66 | 109.74 |
| Quarter Ending Mar-17 | 2.98 | 0.00 | 2.98 | 100.00 |
| Quarter Ending Dec-16 | 3.22 | 2.75 | 0.46 | 14.35 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 1.65 | 1.65 | 2.07 | 1.87 | 1.50 |
| Quarter Ending Sep-18 | 2.04 | 2.04 | 2.41 | 2.41 | 1.50 |
| Year Ending Dec-18 | 6.86 | 6.86 | 8.10 | 9.21 | 11.40 |
| Year Ending Dec-19 | 14.86 | 14.86 | 15.44 | 28.71 | 26.90 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 1 |
| Earnings | ||||
Earnings vs. 
Estimates- BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients
- BRIEF-AnaptysBio Qtrly Loss Per Share $0.30
- BRIEF-Anaptysbio qtrly loss per share $0.45
- BRIEF-AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results